Which MRI scan best spots lung cancer spread to the brain?
NCT ID NCT02250755
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 30 adults with lung cancer that had spread to the brain. Researchers compared two standard MRI sequences (T1 and T2*) to see which one better detects and tracks brain metastases after chemotherapy or targeted therapy. The goal is to improve diagnosis and monitoring without adding extra scans or contrast.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- MRI with gadolinium contrast
- What this could lead to
- If successful, this could help doctors choose the best MRI sequence for diagnosing and tracking brain metastases from lung cancer, improving accuracy without extra tests.
- What could go wrong
- This is a small, completed study with only 30 participants, so results may not apply to all patients. It compares existing techniques, not a new treatment, so impact is limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
30 people
The number who actually took part.
- Start date
-
Jun 2013
- Finished
-
Nov 2015
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Major Patients * Addressed to MRI for initial assessment of brain metastases * At a suspicion of one or more brain metastases in the brain scanner routine screening * Followed for lung cancer histologically documented in the Thoracic Oncology Service of Professor Lafitte (contact: Dr Cortot) * To whom treatment with chemotherapy or targeted therapy (including anti-angiogenic) is considered * Be socially insured- Exclusion Criteria: * Absolute contraindication to MRI (pacemaker, implantable pacemaker, metallic foreign body intraorbital) * Patients minors under guardianship / curatorship * Patients with impaired judgment skills or unable to receive information * Pregnant Women * Patients for which lesions are not compatible with lung metastases * Patients with brain metastases or already known and explored MRI * Patients for whom treatment by surgical excision of brain metastases is considered
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer metastatic to the brain are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital Salengro CHRU de Lille
Lille, 59037, France